Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

31-05-2020 | ASCO 2020 | Conference coverage | Video

Expert comment: Antiandrogens in nonmetastatic CRPC

Tomasz Beer highlights the key messages and caveats of the overall survival data from the PROSPER, SPARTAN, and ARAMIS trials of enzalutamide, apalutamide, and darolutamide, respectively, in the nonmetastatic castration-resistant prostate cancer setting (10:25).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript

Related content

29-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The SPARTAN OS data

23-02-2018 | Prostate cancer | News

Androgen receptor inhibition delays CRPC metastasis

18-02-2019 | Castration-resistant prostate cancer | News

Darolutamide reduces CRPC metastasis risk
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits